Down-regulation of PM20D1 is associated with clinics outcomes and prognosis of gestational patients with diabetes mellitus
IntroductionTo investigate clinic role of PM20D1 in gestational diabetes mellitus (GDM).Material and methodsThis observational study included 189 cases of GDM patients who came to our department during March 2018 to December 2019. Additionally, 100 healthy pregnant individuals who came to physical examination were included as healthy control during the same period. Western blotting was used to determine the expression of PM20D1 at gestational age 24-28 weeks, as well as gestational age 37-40 weeks. Serum inflammatory factors of C reactive protein (CRP), interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α.ResultsThe expression of PM20D1 was markedly decreased in GDM patients compared with the healthy control. Besides, patients of third trimester of pregnancy (gestational age 37-40 weeks) showed significantlylower expression of PM20D1 than patients of second trimester of pregnancy (gestational age 24-28 weeks). Serum levels of CRP, IL-1β, IL-6, TNF-α and leptin were remarkably higher and levels of adiponectin were markedly lower in GDM patients at both second and third trimester of pregnancy, which were the highest at third trimester of pregnancy. Pearson’s analysis showed PM20D1 was negatively correlated with IL-1β, IL-6 and leptin and positively correlated with adiponectin. At second trimester of pregnancy, patients with lower expression of PM20D1 showed remarkably higher levels of HOMA-IR, fasting insulin, FBG, OGTT-1hPG, OGTT-2hPG, as well as TG and LDL-ch, as well as markedly lower levels of HDL-ch. Down-regulated PM20D1 predicted poor pregnancy outcomes.ConclusionsReduced was PM20D1 associated with patients’ clinics outcomes and pregnancy outcomes in GDM.